Search hospitals > Colorado > Golden
National Jewish Health-Western Hematology Oncology
Claim this profileGolden, Colorado 80401
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Leukemia
98 reported clinical trials
9 medical researchers
Summary
National Jewish Health-Western Hematology Oncology is a medical facility located in Golden, Colorado. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Leukemia and other specialties. National Jewish Health-Western Hematology Oncology is involved with conducting 98 clinical trials across 270 conditions. There are 9 research doctors associated with this hospital, such as Nicholas DiBella, Patrick Cobb, MD, Benjamin J. George, and Marwan Massouh.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Lung Cancer
Global LeaderStage IV
Stage III
Stage II
Top PIs
Nicholas DiBellaRocky Mountain Cancer Centers-Boulder5 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
95 reported clinical trials
180 drugs studied
Patrick Cobb, MDSt. Vincent Frontier Cancer Center5 years of reported clinical research
Studies Breast Cancer
Studies Tumors
20 reported clinical trials
42 drugs studied
Benjamin J. GeorgeSCL Health Good Samaritan Medical Center Cancer Centers of Colorado5 years of reported clinical research
Studies Lymphoma
Studies Esophageal Cancer
12 reported clinical trials
48 drugs studied
Marwan MassouhSaint James Community Hospital and Cancer Treatment Center6 years of reported clinical research
Studies Cancer
Studies Lung Cancer
11 reported clinical trials
35 drugs studied
Clinical Trials running at National Jewish Health-Western Hematology Oncology
Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Bladder Cancer
Colorectal Cancer
Cancer
Gastric Cancer
Gastroesophageal Junction Adenocarcinoma
Esophageal Cancer
Fallopian Tube Cancer
Chemotherapy + Hormone Therapy
for Breast Cancer
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Marker-Directed Monitoring
for Breast Cancer
This study is evaluating whether a blood test may help monitor the progression of breast cancer.
Recruiting1 award N/A
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at National Jewish Health-Western Hematology Oncology?
National Jewish Health-Western Hematology Oncology is a medical facility located in Golden, Colorado. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Leukemia and other specialties. National Jewish Health-Western Hematology Oncology is involved with conducting 98 clinical trials across 270 conditions. There are 9 research doctors associated with this hospital, such as Nicholas DiBella, Patrick Cobb, MD, Benjamin J. George, and Marwan Massouh.